Phase 2 HOPE clinical trial results
Theodore Mavridis and Messoud Ashina discuss the Phase 2 HOPE clinical trial findings for Lu AG09222. The study assessed the drug's efficacy and safety for migraine prevention, focusing on its role in targeting the PACAP pathway.